Telmisartan Okayed for Cardiovascular Risk Reduction

Share this content:

Boehringer Ingelheim Pharmaceuticals has received approval for a new indication for its angiotensin II receptor blocker Micardis (telmisartan): cardiovascular risk reduction in patients aged 55 years and older who are at high risk of experiencing major cardiovascular events and are unable to take ACE inhibitors.

The FDA also approved a New Drug Application for the two-drug combination Twynsta (telmisartan/amlodipine) as a treatment for hypertension.

“For those at high risk of cardiovascular events, it's important to find a treatment that helps reduce their risk. Further, two-thirds of people currently treated for hypertension are not at target blood pressure goals,” said James Young, MD, Professor of Medicine and Executive Dean of the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.

“The newly approved use of telmisartan for cardiovascular risk reduction in high-risk patients who are unable to take an ACE inhibitor, and the availability of a telmisartan-amlodipine combination for hypertension, give patients and physicians much needed new treatment options for these chronic health problems.”

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup